Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
Hypertrophic Cardiomyopathy (HCM) is a relatively common inherited heart muscle disease. Many
patients experience symptoms of breathlessness, fatigue and chest pain. These symptoms are
not always controlled with current therapies.
Recently the investigators showed that a drug called Perhexiline markedly improved exercise
capacity and symptoms in patients with heart failure. In this proposal the investigators wish
to test whether Perhexiline improves exercise capacity and relieves symptoms in patients with
HCM
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital Birmingham
Collaborators:
British Heart Foundation University College London Hospitals University of Oxford